You probably first heard about peptides on a podcast.
Maybe Diary of a CEO. Dr. Alex Tatem ran 90 minutes with Steven Bartlett in April. Cognitive performance. Sleep. GLP-1s. Anti-aging. The FDA had quietly banned 19 peptides. RFK Jr. reversed it. The whole conversation framed peptides as the secret big pharma had been hiding.
That episode leaned into the hype. The science underneath it didn't need to.
Peptides are now the most-watched therapeutic category in pharma. The pipeline behind GLP-1s is going to push pharmacy spend, plan design, and PBM economics into a different shape over the next decade.
So which peptides are about to hit your formulary, and what will they cost?
What is a peptide?
Short chain of amino acids. Bigger than a small-molecule pill. Smaller than a protein-based biologic.
Peptides bind targets with the precision of a biologic but can be designed and manufactured at something closer to small-molecule scale. They don't survive the gut easily, which is why most are injected. That's changing. Oral peptides are arriving.
The category isn't new. Insulin is a peptide. So is calcitonin. What's new is the manufacturing capacity to scale them, the AI-driven design pipelines, and the realization that peptides can hit targets small molecules can't.
What's already covered on your plan?
The GLP-1 drugs you know about are peptides. Semaglutide (Ozempic, Wegovy). Tirzepatide (Mounjaro, Zepbound). Now cleared for diabetes, obesity, sleep apnea, cardiovascular event reduction, and kidney disease. That alone is a $50B+ revenue line and still growing.
CagriSema, Novo's combination of cagrilintide and semaglutide, has an FDA decision expected October 2026.
What I've seen with my own eyes
I'll level with you. The clinical literature is one thing. Watching this play out in your own circle is another.
Friends down 50, 60, 80, 130 pounds. People who fought their weight for 30 years finally winning. A business owner I work with told me his knees feel 20 years younger. A diabetic friend off insulin entirely. Another buddy, first time in his adult life he doesn't constantly think about the next meal.
I've sat across the table from CEOs who couldn't get out of their own way for a decade and now look like a different person. Their teams notice. Their families notice.
This isn't a passing diet drug. These molecules are changing lives. The spreadsheet doesn't always capture this full impact. These drugs are about to make that spreadsheet comparison pretty brutal though.
What's coming, and when
Retatrutide. Lilly's triple agonist. Hits GLP-1, GIP, and glucagon receptors. TRIUMPH-4 reported 28.7% weight loss at 68 weeks, the highest in the class. Seven Phase 3 readouts roll through 2026. Approval likely 2027. The first trillion dollar drug?
Orforglipron. Watch this one for sheer scale. Oral GLP-1, small molecule, no cold chain, no injection. ATTAIN-1 reported 12.4% weight loss. NDA filing in 2026. If oral GLP-1s work at scale, the global access curve flips overnight.
MariTide. Amgen's once-monthly injectable. Phase 2 showed 12% to 16% weight loss. Monthly dosing changes adherence math entirely.
Survodutide. Boehringer's dual GLP-1/glucagon agonist, Phase 3, with liver disease (MASH) on the indication list.
Beyond metabolic, peptide programs are accelerating in oncology, autoimmune disease, antimicrobials, and regenerative medicine. The investment numbers are loud. Novartis closed a $1.7B peptide design deal with Unnatural Products. Novo Nordisk wrote a $2.1B partnership with Vivtex on oral delivery.
Peptide pipeline at a glance
| Drug | Maker | Type | Stage | Expected impact |
|---|---|---|---|---|
| Semaglutide | Novo Nordisk | GLP-1 | Approved | Class anchor, now MFN-priced |
| Tirzepatide | Eli Lilly | GLP-1/GIP dual | Approved | Higher efficacy, expanded indications |
| CagriSema | Novo Nordisk | Amylin + GLP-1 | FDA decision Oct 2026 | Next launch wave |
| Retatrutide | Eli Lilly | GLP-1/GIP/glucagon triple | Phase 3 | Highest weight loss in class |
| Orforglipron | Eli Lilly | Oral GLP-1 small molecule | NDA 2026 | Removes cold chain, scales globally |
| MariTide | Amgen | Monthly GLP-1 | Phase 3 | Adherence shift |
| Survodutide | Boehringer | GLP-1/glucagon dual | Phase 3 | Liver disease indication |
Are peptides different than previous drug breakthroughs?
Three things make this category structurally different.
Generics will be slow. Peptide manufacturing is harder than small-molecule chemistry. Biosimilar peptides take longer to validate and approve. When tirzepatide loses exclusivity around 2036 to 2039, price erosion won't look like a typical pill going generic. Branded pricing power holds longer.
Indications keep expanding. SELECT showed cardiovascular benefit. FLOW showed kidney benefit. Sleep apnea got its own indication. Alzheimer's, alcohol use disorder, and Parkinson's trials are reading out. Each new indication enlarges the eligible population without a new molecule.
Supply is being rebuilt from scratch. Lilly committed $27B in US manufacturing. Novo committed $10B more. Amgen, Pfizer, and others are following. Capacity is years of work, not months.
What does the release of new peptides do to pharmacy spend?
Pharmacy trend hasn't been calm in years. Specialty has been driving trend into the 8% to 12% range for the better part of a decade. Oncology, autoimmune, rare disease, gene therapy. GLP-1s didn't break that line. They steepened it.
Plans covering obesity indications are running 15% to 25% pharmacy trend now. The pipeline outlined will keep that pressure on through at least 2030. New molecules launch at premium prices. Each new indication enlarges the covered pool. Manufacturers protect pricing power until oral and biosimilar competition arrives.
The counterforces are real but uneven. LillyDirect at $299 to $449, NovoCare at $149 to $349, and TrumpRx around $350 average put a $1,300 list-price drug in reach for self-pay members. That doesn't lower your plan cost. It changes what "no coverage" means for the participant. The Medicare GLP-1 Bridge through December 2027 takes some pressure off active employees about to roll into Part D.
The bottom line
Peptides aren't a secret. They're the most-funded category in pharma, the most-watched pipeline in 30 years, and the most life-changing drug class I've seen up close in my career.
They're also expensive, expanding, and slow to go generic.
Plan accordingly.